Evidence map›Paper›PMID 41161912›Full record

ReviewRheumatic diseases clinics of North America2025

The Mythology of Polymyositis.

Suur Biliciler, Tahseen Mozaffar

Abstract readReviewHistorical Article
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatic diseases clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suur BilicilerDepartment of Neurology, UT Houston, McGovern Medical School, University of Texas, MSE#466 6431 Fannin Street, Houston, TX 77030, USA.
Tahseen MozaffarDepartment of Neurology and Pathology & Laboratory Medicine, Institute of Immunolog, Muscle Biology and Disease Research Center, University of California, Irvine. Electronic address: mozaffar@uci.edu.

Funding

Institute for Clinical and Translational ScienceUM1TR004927 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAN M COOPER, Eric J. Vilain · 2024 to 2026
$12.2M
High-dimensional mass imaging of muscle for the mechanistic study of T cells in inclusion body myositisR21AR082649 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2023 to 2024
$544k
Isolation of HIV NAbs from a nonimmune yeast-display library of scFv antibodiesR21AI074457 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI GRAY, SEAN ALEX · 2008 to 2009
$525k
NCATS NIH HHS UM1 TR004927NIAID NIH HHS R21 AI074457NIAMS NIH HHS R21 AR082649
6 · The paper itself

Abstract

Polymyositis (PM) has been in the diagnostic armamentarium in medicine since the mid-nineteenth century. Medicine training puts a heavy emphasis on this diagnosis, and anyone with proximal muscle weakness with elevated serum creatinine kinase is assumed to be PM and a number of patients were rendered this diagnosis without additional testing. This article addresses the historical aspects of the diagnosis of PM and its evolution. We review this literature that addresses the rarity of this diagnosis and rightly puts in perspective in terms of its occurrence in relation to other inflammatory myositides.

Indexed as

PolymyositisHistory, 19th CenturyHistory, 20th CenturyHumansInclusion body myositisMyopathologyMyositisMythologyPolymyositis

Identifiers

PMID41161912
PMCPMC13098319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.